 | Up a level |
Elzi, L; Schlegel, M; Weber, R; Hirschel, B; Cavassini, M; Schmid, P; Bernasconi, E; Rickenbach, M; Furrer, H; Swiss, HIV Cohort Study (2007). Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clinical infectious diseases, 44(1), pp. 94-102. Cary, N.C.: The University of Chicago Press 10.1086/510080
Ledergerber, B; Furrer, H; Rickenbach, M; Lehmann, R; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Egger, M; Weber, R; Swiss, HIV Cohort Study (2007). Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical infectious diseases, 45(1), pp. 111-9. Cary, N.C.: The University of Chicago Press 10.1086/518619
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss, HIV Cohort Study (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8), pp. 1165-73. London: International Medical Press
Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Wolbers, M; Battegay, M; Hirschel, B; Furrer, H; Cavassini, M; Hasse, B; Vernazza, PL; Bernasconi, E; Kaufmann, G; Bucher, HC; Swiss, HIV Cohort Study (2007). CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy, 12(6), pp. 889-97. London: International Medical Press
Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; Swiss, HIV Cohort Study (2007). Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics, 17(9), pp. 755-64. London: Lippincott Williams & Wilkins 10.1097/FPC.0b013e32814db8b7
Glass, TR; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2007). Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV clinical trials, 8(2), pp. 77-85. St. Louis, Mo.: Thomas Land Publishers 10.1310/hct0802-77
Müller, NJ; Furrer, H; Kaiser, L; Hirschel, B; Cavassini, M; Fellay, J; Chave, JP; Wüthrich, RP; Weber, M; Müllhaupt, B; Candinas, D; Reichen, J; Giostra, E; Mentha, G; Halkic, N; Hirsch, HH; Weber, R; Swiss, HIV Cohort Study (2006). HIV and solid organ transplantation: the Swiss experience. Swiss medical weekly, 136(11-12), pp. 194-6. Muttenz: EMH Schweizerischer Ärzteverlag
Colombo, S; Buclin, T; Décosterd, LA; Telenti, A; Furrer, H; Lee, BL; Biollaz, J; Eap, CB; Swiss, HIV Cohort Study (2006). Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology & therapeutics, 80(4), pp. 307-18. New York, N.Y.: Nature Publishing Group 10.1016/j.clpt.2006.06.006
Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2006). Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine, 7(6), pp. 404-10. Oxford: Blackwell Science 10.1111/j.1468-1293.2006.00400.x
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Colombo, S; Telenti, A; Buclin, T; Furrer, H; Lee, BL; Biollaz, J; Decosterd, LA; Swiss, HIV Cohort Study (2006). Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Therapeutic drug monitoring, 28(3), pp. 332-8. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.ftd.0000211807.74192.62
Bertschy, S; Opravil, M; Cavassini, M; Bernasconi, E; Schiffer, V; Schmid, P; Flepp, M; Chave, JP; Christen, A; Furrer, H; Swiss, HIV Cohort Study (2006). Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clinical microbiology and infection, 12(7), pp. 666-71. Oxford: Blackwell Publishing 10.1111/j.1469-0691.2006.01459.x
Zinkernagel, AS; von Wyl, V; Ledergerber, B; Rickenbach, M; Furrer, H; Battegay, M; Hirschel, B; Tarr, PE; Opravil, M; Bernasconi, E; Schmid, P; Weber, R; Swiss, HIV Cohort Study (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy, 11(2), pp. 131-42. London: International Medical Press
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Karrer, U; Ledergerber, B; Furrer, H; Elzi, L; Battegay, M; Cavassini, M; Gayet-Ageron, A; Hirschel, B; Schmid, P; Russotti, M; Weber, R; Speck, RF; Swiss, HIV Cohort Study (2005). Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS, 19(17), pp. 1987-94. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000194136.73876.9c
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Wunder, D; Bersinger, NA; Fux, C; Weber, R; Bernasconi, E; Cavassini, M; Bucher, HC; Schiffer, V; Schmid, P; Furrer, H; Swiss, HIV Cohort Study (2005). Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS, 19(16), pp. 1837-42. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000189852.21441.2a
Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531
Colombo, S; Soranzo, N; Rotger, M; Sprenger, R; Bleiber, G; Furrer, H; Buclin, T; Goldstein, D; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and genomics, 15(9), pp. 599-608. London: Lippincott Williams & Wilkins 10.1097/01.fpc.0000172241.42546.d3
Rauch, A; Rickenbach, M; Weber, R; Hirschel, B; Tarr, PE; Bucher, HC; Vernazza, P; Bernasconi, E; Zinkernagel, AS; Evison, J; Furrer, H; Swiss, HIV Cohort Study (2005). Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases, 41(3), pp. 395-402. Cary, N.C.: The University of Chicago Press 10.1086/431486
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Rotger, M; Colombo, S; Furrer, H; Bleiber, G; Buclin, T; Lee, BL; Keiser, O; Biollaz, J; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics, 15(1), pp. 1-5. London: Lippincott Williams & Wilkins
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Rauch, A; Egger, M; Reichen, J; Furrer, H; Swiss, HIV Cohort Study (2005). Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. Journal of acquired immune deficiency syndromes JAIDS, 38(2), pp. 238-40. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/01.qai.0000148535.97081.72
